Tender detail
Supply of Serplulimab for the B.6 drug programme
Summary
The Institute of Tuberculosis and Lung Diseases is procuring the medicinal product Serplulimab for settlement under drug programme B.6, for the treatment of small-cell and non-small-cell cancer.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.